27 results about "Triamcinolone acetonide" patented technology

The invention provides a compound nystatin ointment and a preparation method thereof, and relates to the technical field of medicine preparation, the compound nystatin ointment comprises active ingredients of nystatin, neomycin sulfate, triamcinolone acetonide and permethrin, and the formula comprises liquid paraffin, white vaseline, wool fat, hexadecanol, PEG-30 dipolyhydroxystearate and glyceryl monoisostearate. According to the compound nystatin ointment preparation prescription process disclosed by the invention, the phenomenon of ointment matrix layering in the use process of commercially available products is mainly solved. According to a pharmaceutical research test, the stability of the compound nystatin ointment is superior to that of a commercially available original development agent, the ointment body character and the stability of active ingredients can be kept under the conditions of high temperature, high humidity, low temperature, freeze thawing and illumination, the maximum single impurity content and the total impurity content in the product are not obviously increased, and the quality is controllable. And meanwhile, an in-vitro transdermal test (IVPT) accidentally finds that the retention amount of related active ingredients is higher than that of the original development agent, and the drug effect is obviously improved. Through clinical test research, the compound nystatin ointment disclosed by the invention can be used for effectively treating external otitis caused by bacteria sensitive to neomycin, fungi sensitive to nystatin and ear mites sensitive to permethrin of dogs and cats.

The invention relates to the field of medicinal emulsifiable paste, in particular to compound fluconazole emulsifiable paste and a preparation method thereof. The compound fluconazole emulsifiable paste is prepared from the following components in parts by weight: 0.6 to 5 parts of fluconazole, 0.2 to 2 parts of neomycin sulfate, 0.1 to 0.2 part of triamcinolone acetonide, 5 to 15 parts of stearic acid, 10 to 25 parts of white vaseline, 2 to 8 parts of glyceryl monostearate, 0.5 to 3 parts of medicinal dimeticone, 1 to 5 parts of polysorbate-80, 0.1 to 0.3 part of sorbic acid, 0.1 to 1 part of vitamin E, 0.01 to 0.1 part of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 5 to 15 parts of glycerol and the balance of purified water, wherein the total amount is 100 parts. According to the application, the antioxidant property of the cream is improved by adding the vitamin E and the EDTA disodium, the vitamin E is used for directly scavenging free radicals, the EDTA disodium is used for eliminating an oxidation catalyst, and the quality guarantee period of the cream can be remarkably prolonged and the drug effect can be maintained by combining the vitamin E and the EDTA disodium.

The present invention belongs to the technical field of veterinary preparations, and specifically relates to a veterinary enrofloxacin compound gel ear drops and its preparation method and application. The compound gel ear drops include four active substances: enrofloxacin, triamcinolone acetonide, gentamicin sulfate, and pulegone. The preparation method is to add poloxamer, L-cysteine, and carbomer to water, stir and add benzyl alcohol to obtain solution A, dissolve low-erucic acid rapeseed oil in ethanol of more than 85%, add enrofloxacin, triamcinolone acetonide, pulegone, and gentamicin sulfate to obtain solution B; slowly add solution B to the gel matrix of solution A to obtain solution C, and then filter to obtain the compound gel. Pharmacodynamic experiments have confirmed that it has a good therapeutic effect on inflammation of the external ear canal of pets; accelerated experiments have confirmed that the compound gel is stable in nature, can be stored for a long time, and is suitable for further expansion of production.

The invention discloses a pharmaceutical composition for preventing esophageal stenosis. The pharmaceutical composition consists of glucocorticoid and sesame oil, the glucocorticoid is triamcinolone acetonide or dexamethasone. The pharmaceutical composition provided by the invention is prepared from 1-5 parts by weight of triamcinolone acetonide and 10-15 parts by weight of sesame oil; or 5-10 parts by weight of dexamethasone and 100 parts by weight of sesame oil. The medicine composition is simple, raw materials are low in price, and mass production and use are facilitated. Practical research finds that the pharmaceutical composition provided by the invention can be used for preventing esophageal stenosis caused by disease reasons, such as esophageal stenosis after large-area endoscopic submucosal dissection (the dissection area is 2 / 3 or above) of esophageal premature cancer, esophageal restenosis after benign esophageal stenosis dilation treatment and the like.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The invention relates to the technical field of perovskite thin films, in particular to a preparation method of a fluorine-containing steroid molecule regulated perovskite thin film, the perovskite thin film and a photovoltaic device.The perovskite thin film comprises a precursor composition, the precursor composition is a perovskite precursor salt solution, and the perovskite precursor salt solution is composed of precursor salt, a solvent system and fluorine-containing steroid molecules Dex, the precursor salt is Cs0.05 (FA0.95 MA0.05) 0.95 Pb (I0.95 BT0.05) 3, the precursor salt comprises FAI, PbI2, MACl, PbBr2, CsI and MABr, the fluorine-containing steroid molecule Dex has a steroid ring rigid skeleton and simultaneously contains = O,-OH and C-F functional sites, the fluorine-containing steroid molecule Dex is preferably dexamethasone Dex, and the fluorine-containing steroid molecule Dex is replaced by prednisolone, triamcinolone acetonide and flumetasone; the solvent system is composed of DMP and NMP, the volume ratio of DMP to NMP is 4: 1, and the solvent system contains an organic solvent. The semitransparent perovskite thin film prepared by the invention has high transmittance and excellent crystallization quality, and the open-circuit voltage, the fill factor and the operation and storage stability of a prepared device are remarkably improved.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

The invention discloses a compound nysfungin ointment, which comprises an active component, a preservative, a humectant, a thickening agent, a grease matrix and an antibacterial agent, the active component is selected from one or more of self-made mycotoxin, neomycin sulfate, permethrin and triamcinolone acetonide, the preservative is selected from benzalkonium chloride, the humectant is selected from glycerol, the thickening agent is selected from glycerol, and the grease matrix is selected from a grease matrix. The humectant is selected from humectant, the thickening agent is selected from carbomer, the grease matrix is selected from liquid paraffin and / or wool fat, the antibacterial agent is selected from thymol, and the ratio of the humectant to the thickening agent is (2-7): (0.5-3) in parts by mass. By accurately controlling the proportion of the humectant to the thickener, the texture of the ointment can be optimized, so that the skin permeability is improved, the medicine absorption is promoted, the treatment effect is improved, in addition, the form of the ointment can be kept, the active ingredients are prevented from being degraded, and the shelf life of the preparation is prolonged.

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

The present disclosure relates to pharmaceutical suspensions of triamcinolone acetonide, methods of producing such suspensions and methods of using of such suspensions. The pharmaceutical suspensions of the present disclosure are stable and suitable for administration by suprachoroidal injection through a 30-gauge microneedle.

The invention relates to the technical field of medicines, in particular to triamcinolone acetonide palmitate nano-emulsion as well as a preparation method and application thereof. The composition comprises a water phase and an oil phase, the oil phase comprises triamcinolone acetonide palmitate, a surfactant, oil and a cosurfactant; the water phase comprises an osmotic pressure regulator and a charge modifier. In the triamcinolone acetonide palmitate nano-emulsion, the content ratio of the oil to the surfactant is (3: 1)-(1: 1). According to the preparation method of the triamcinolone acetonide palmitate nano-emulsion provided by the invention, a phase transformation method is adopted, and the average particle size of the triamcinolone acetonide palmitate nano-emulsion is accurately controlled by changing the dosage of the oil phase and the surfactant, so that the triamcinolone acetonide palmitate nano-emulsion suitable for eye iontophoresis is obtained. Meanwhile, it is further found that the permeability of the triamcinolone acetonide palmitate nano-emulsion can be remarkably enhanced by adding cations into the triamcinolone acetonide palmitate nano-emulsion, and the delivery efficiency is enhanced.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a compound ointment preparation for treating fungal infection and a preparation method and application thereof. According to the compound ointment preparation, chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide compound serve as core components, no chemical incompatibility exists among chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide, and comprehensive treatment on external auditory canal mycosis is achieved through the pharmacological synergistic effect. Meanwhile, adaptive plant essential oil is specially selected, and the proportion of active ingredients is optimized, so that the compound ointment preparation can effectively control bacteria, fungi and inflammation, the hormone amount is obviously reduced, and side effects are reduced.

A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

The invention relates to topical ophthalmic formulations of triamcinolone acetonide-loaded liposomes for the prevention of macular thickening and its associated visual outcomes following lens surgery. The liposome formulation comprises thermodynamically self-forming liposomes that are useful topically for treating diseases of the posterior segment of the eye.

The invention relates to the technical field of scar treatment, in particular to a triamcinolone acetonide patch and a preparation device.The triamcinolone acetonide patch comprises a hydrogel layer, a microneedle drug delivery layer and a pain relieving layer which are sequentially compounded from outside to inside, hollow parts are arranged in the hollow microneedles, the hollow parts are filled with triamcinolone acetonide liquid medicine, the top ends of the hollow microneedles are fixedly connected with elastic assemblies, and the elastic assemblies automatically retract into the microneedle administration layer after releasing medicine. Through a three-layer structure composed of the hydrogel layer, the microneedle drug delivery layer with the temperature-sensitive elastic assembly and the cream layer containing lidocaine, convenient, low-pain and safe drug delivery of scars is achieved, and meanwhile efficient and accurate production is guaranteed by matching with an integrated preparation device.

The invention belongs to the technical field of biomedical materials, and particularly relates to a drug-loaded microneedle patch for inhibiting keloid hyperplasia and a preparation method of the drug-loaded microneedle patch. The drug-loaded microneedle patch comprises the following raw materials in parts by weight: 100 parts of an antioxidant polymer carrier, 1-5 parts of 5-fluorouracil, 0.5-3 parts of triamcinolone acetonide, 1-4 parts of a cross-linking agent and 30-60 parts of a biocompatible polymer, the antioxidant polymer carrier is composed of hyaluronic acid, ROS responsive cross-linking bridge molecules and Prussian blue nanoparticles, and the microneedle adopts a core-shell structure design. A shell layer is loaded with a quick-acting anti-proliferation drug 5-fluorouracil, a core layer is loaded with a long-acting anti-inflammatory drug triamcinolone acetonide, and the cross-linking density of the core layer is higher than that of the shell layer, so that time-divided release of the drugs is realized, and the constructed drug-loaded microneedle patch can respond to a scar microenvironment to remove excessive active oxygen and synergistically inhibit keloid hyperplasia.

The present invention relates to the technical field of organic synthesis. Disclosed is a crystal-form-controllable triamcinolone acetonide preparation method. Triamcinolone acetonide has two crystal forms, i.e. crystal form 1 and crystal form 2, respectively. The method comprises: for crystal form 1, adding ethanol to a crude product of triamcinolone acetonide for dissolution under reflux, cooling and stirring the mixture for crystallization, and performing filtering to obtain a wet product of triamcinolone acetonide; adding ethanol for dissolution under reflux, adding water to a reflux solution and controlling the temperature of the system to be 70-80ºC; and after the addition of water is complete, cooling and stirring for crystallization to obtain single crystal form 1 of triamcinolone acetonide having a low organic solvent content; and for crystal form 2, adding ethanol to a crude product of triamcinolone acetonide for dissolution under reflux, cooling and stirring the mixture for crystallization, and performing filtering to obtain a wet product of triamcinolone acetonide; adding ethanol for dissolution under reflux, cooling and stirring the mixture for crystallization to obtain single crystal form 2 of triamcinolone acetonide having a low organic solvent content. The triamcinolone acetonide preparation method of the present invention achieves crystal form controllability, high purity, and low solvent residual amount, and can prepare a product of a single crystal form according to requirements, with strong controllability, easy method production, and high process stability.

The invention relates to self-adhesive gel as well as a preparation method and application thereof. The self-adhesive gel disclosed by the invention is prepared from the following components: germanene, polydimethylsiloxane, polyvinylpyrrolidone, triamcinolone acetonide, absolute ethyl alcohol and water. When the self-adhesive gel is used, ethanol and water in the self-adhesive gel can be quickly volatilized to form a layer of self-adhesive polymer film which is firmly adsorbed on the surface of a tissue, meanwhile, polydimethylsiloxane can retain water, germanene has a photo-thermal effect and is beneficial to promoting diffusion and absorption of triamcinolone acetonide to the tissue, and the prepared self-adhesive gel can be used for preparing a scar repair medicament.

A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

The invention relates to a triamcinolone acetonide and econazole cream for promoting barrier repair and a preparation method of the triamcinolone acetonide and econazole cream. According to the triamcinolone acetonide and econazole cream, the brown algae extract rich in fucosan is creatively introduced, so that the triamcinolone acetonide and econazole cream keeps the original anti-inflammatory and anti-fungal curative effects, meanwhile, the risks of local adverse reactions such as skin atrophy and angiotelectasis caused by triamcinolone acetonide are effectively relieved, generation of fungal drug resistance is inhibited, and the triamcinolone acetonide and econazole cream has a good application prospect. The barrier repairing and moisturizing capabilities of the skin are obviously enhanced. Besides, the red algae extract is introduced into the cream formula, and the red algae extract and the brown algae extract play a synergistic effect, so that local adverse reactions are further relieved, fungal drug resistance is inhibited, and the barrier repairing and moisturizing capacity of the skin is enhanced.

The invention relates to the technical field of medical instruments, and discloses a composite hyaluronic acid beauty fluid formula, which comprises 2 ml of levocarnitine, 2 ml of furosemide, 2 ml of gastrodin, 1 ml of dexamethasone, 3 ml of triamcinolone acetonide, 1 ml of auxin, 3 ml of lidocaine, and 100 ml of saline water. Through two-way regulation and control, tissue regeneration is not stimulated, the healing property is high, and the problem caused by excessive filling of regenerative materials can be rapidly solved.

The present disclosure provides a method for manufacturing a crosslinked hyaluronic acid gel and a crosslinked hyaluronic acid gel. The crosslinked hyaluronic acid gel contains substantially evenly distributed triamcinolone.

The application provides a drug-loaded substrate, which is modified with a coating layer containing chitosan and triamcinolone acetonide. The combination of triamcinolone acetonide and chitosan in the drug-loaded substrate of the application can significantly promote the healing of the epithelial mucosa of the urinary tract and digestive tract and inhibit scar formation while inhibiting bacteria, and is a good material for preparing medical devices such as catheters.

The invention belongs to the technical field of biological medicines, and particularly relates to triamcinolone acetonide-polylactic acid sustained-release microspheres with uniform particle size as well as a preparation method and application of the triamcinolone acetonide-polylactic acid sustained-release microspheres. The triamcinolone acetonide sustained-release microsphere for injection takes triamcinolone acetonide as an effective component and polylactic acid as a carrier, and SPAN of the triamcinolone acetonide sustained-release microsphere for injection is less than or equal to 1.5. The triamcinolone acetonide sustained-release microspheres obtained by adopting the preparation method are narrower in particle size distribution, more stable in in-vitro release and small in batch difference, can pass through a very small injection needle, are more suitable for injection of subcutaneous layers, deep dermis layers and superficial dermis layers, and have wide clinical application prospects in the field of skin nodule and scar treatment.

The application discloses triamcinolone acetonide sustained-release microspheres for injection (with special solvent) and a preparation method and application thereof. It is found through experiments that the triamcinolone acetonide sustained-release microspheres prepared by the method have higher stability, a longer effective period, more gentle release, longer maintenance time of drug efficacy and a significantly longer release period, and have a wide clinical application prospect in the field of osteoarthritis treatment.